Other trauma applications
Preclinical studies in a variety of models indicate that VANADIS® has a good chance to become a successful treatment in indications like stroke, surgery and multiple organ dysfunction syndrome (MODS).
Another example is acute kidney injury:
Acute kidney injury application
Acute kidney injury (AKI) is caused by an inflammatory process in the kidney that can lead to loss of kidney function. AKI affects about 2 million patients annually in Europe, the USA and Japan, from which about 700,000 patients die.
The most common cause of AKI in intensive – care patients is an inflammatory process that can lead to an acute tubule necrosis and loss of kidney function. which in general will be caused by renal ischemia (hypotension, sepsis), and toxic causes (drugs or contrast medium) or a combination of both.
AKI is experienced in no less than 4% of hospital admissions and 40% of the intensive-care (mostly trauma) admissions. Depending on the severity and cause of the kidney damage, the percentage of deaths varies from 10% to 70%.
Preclinical studies have demonstrated that the use of VANADIS® in AKI reduces reperfusion damage in the kidneys significantly.